NATALEE 6-Year Update: Overall Survival Benefit With Ribociclib | ESMO 2026
More on breast cancer
evERA Dr. Sara TolaneyevERA : Giredestrant + Everolimus: evERA Biomarker Analyses | Sara Tolaney | ESMO 2026
Dr. Sara Tolaney. Trial update. ESMO 2026.
TOP-1 TrialDr. Elisabetta BonzanoTOP-1 Trial: Can We Omit Both Radiotherapy and Endocrine Therapy?
Dr. Elisabetta Bonzano. Expert pick. ESMO 2026. Day 2.
- Can we safely combine radiotherapy with antibody-drug conjugates—or does the specific ADC change the risk?
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
Publication pick. Radiotherapy & Oncology. October 15, 2026.
- Is precision breast cancer care entering a new era, or are complexity, biomarker uncertainty, and unequal access holding it back?
Advances in Systemic Treatment of Breast Cancer (Review)
Publication pick. NEJM. October 12, 2026.
- Can a blood test detect cancer earlier—but still fail to demonstrate clinical utility?
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
- FDA NEWS: HER2CLIMB-05 Update
FDA NEWS: HER2CLIMB-05 Update
Regulatory news. FDA. October 7, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.